The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.
The firm will use the proceeds to advance AIR-001 as its lead candidate and file a clinical trial application later this year.
The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback